European Directorate for the Quality of Medicines & HealthCare | Direction européenne de la qualité du médicament & soins de santé

COUNCIL OF EUROPE
CONSEIL DE L'EUROPE

Certification of Substances Department

Certificate of suitability
No. R0-CEP 2018-174 - Rev 01

Name of the substance:
DESLORATADINE

Name of holder:
HAINAN POLY PHARMACEUTICAL COMPANY LIMITED
Guilinyang Economic Development Area
Meilan District
China-571 127 Haikou, Hainan Province

Site(s) of production:
SEE ANNEX 1

THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE
R0-CEP 2018-174 - REV 00

After examination of the information provided on the manufacturing method and subsequent processes (including purification) for this substance on the site(s) of production listed in annex, we certify that the quality of the substance is suitably controlled by the current version of the monograph **DESLORATADINE** no. 2570 of the European Pharmacopoeia, current edition including supplements, only if it is supplemented by the test(s) mentioned below, based on the analytical procedure(s) given in annex.

– Test for residual solvents by gas chromatography (Annex 2)
Ethyl acetate not more than 5000 ppm

A risk management summary for elemental impurities has been provided. (Annex 3)

The re-test period of the substance is 36 months if stored in two triple laminated bags (polyethylene terephthalate/ aluminium/ polyethylene), placed in a fibre drum.

The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.

The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.

Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice and in accordance with the dossier submitted.

Failure to comply with these provisions will render this certificate void.

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)
Tel: +33 (0) 3 88 41 30 30 – e-mail: cep@edqm.eu
Internet: http://www.edqm.eu

This certificate is granted within the framework of the procedure established by the European Pharmacopoeia Commission [Resolution AP-CSP (07) 1] for a period of five years starting from **9 May 2019**. Moreover, it is granted according to the provisions of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent amendment, and the related guidelines.

This certificate has three annexes, the first of 1 page, the second of 2 pages and the third of 1 page.

This certificate has:

lines.

On behalf of the
Director of EDQM

Strasbourg, 16 March 2022

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

HAINAN POLY PHARMACEUTICAL COMPANY LIMITED, as holder of the certificate of suitability

R0-CEP 2018-174 - Rev 01 for Desloratadine

hereby authorises .....

(*name of the pharmaceutical company*)

to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): (*name of product(s) and marketing number(s), if known*)

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature (*of the CEP holder*):

Certification of Substances Department

Annex 1: Site(s) of production for R0-CEP 2018-174 - Rev 01

Production of intermediate(s):

MOREPEN LABORATORIES LIMITED
Village Masulkhana, Parwanoo, Solan District
India-173 220 Masulkhana, Himachal Pradesh

Production of Desloratadine:

HAINAN POLY PHARMACEUTICAL COMPANY LIMITED
Guilinyang Economic Development Area
Meilan District
China-571 127 Haikou, Hainan Province

Residual solvents	Ph. Eur. <2.2.28>: By GC *Chromatographic conditions* The GC chromatographic condition as follows: Column: quartz capillary column (Agilent DB-624, 30m×0.53mm×3.0μm or equivalent) with 6% cyanpropyl p henyl-94%phoydimethylsiloxane as stationary phase Detector: FID Oven temperature: keep at 40 °C for 10 min, then raise to 140 °C at a speed of 20 °C/min and maintain for 20 min; Temperature of injection port: 140 °C Temperature of detector: 260 °C Carrier gas: nitrogen Flow rate: 2.0 ml/min Split ratio is 1:5 Head-space conditions that may be used: Headspace vial temperature: 90 °C Temperature of LOOP tube: 100 °C TRLINE temperature: 110 °C Injection circulation time: 45 min Heat preservation time of headspace vial: 45 min Pressurizing time: 0.5 min Injection time: 1 min Loop EQ Time: 0.05 min Loop Fill Time: 0.2 min Injection volume is 1 ml. *System suitability* For 6 replicate injections of reference solution, peak area RSD of ethanol and ethyl acetate is not more than 10.0%.

Test Items	Analytical procedures
	Reference solution: accurately weigh suitable amount of ethanol and ethyl acetate, dilute with dimethyl sulfoxide (DMSO) to obtain a mixed solution containing 1mg/ml of ethanol and acetic ether respectively. Accurately transfer 5.0ml of the solution to headspace vial, cover and seal. *Test solution*: take about 1.0 g of the substance to be examined, accurately weighed, transfer to headspace vial, accurately add 5.0 mL of dimethyl sulfoxide, seal the vial, and dissolve by shaking, as test solution. *Procedure* Take test solution and reference solution, measure by headspace injection method, record the chromatograms. Calculate the residual amount of each solvent according to the formula below. It contains no more than 0.5% of ethanol and no more than 0.5% of ethyl acetate. $$\text{Residual solvent (\%)} = \frac{C_s \times A_u}{C_u \times A_s} \times 100\%$$ In which, C_s: concentration of each solvent in reference solution, mg/ml, A_u: peak area of each solvent in test solution, A_s: average peak area of each solvent in reference solution, C_u: concentration of Desloratadine in test solution, mg/ml.

Risk Management Summary of Elemental Impurities in Desloratadine

Intended route of asministration / Use of the substance: Oral				
Element	**Class**	**Intentionally added?**	**Considered in risk management?**	**Conclusion**
Cd	1	No	Yes	Absent
Pb	1	No	Yes	Absent
As	1	No	Yes	Absent
Hg	1	No	Yes	Absent
Co	2A	No	Yes	Absent
V	2A	No	Yes	Absent
Ni	2A	No	Yes	Absent
Tl	2B	No	No	N/A
Au	2B	No	No	N/A
Pd	2B	No	No	N/A
Ir	2B	No	No	N/A
Os	2B	No	No	N/A
Rh	2B	No	No	N/A
Ru	2B	No	No	N/A
Se	2B	No	No	N/A
Ag	2B	No	No	N/A
Pt	2B	No	No	N/A
Li	3	No	No	N/A
Sb	3	No	No	N/A
Ba	3	No	No	N/A
Mo	3	No	Yes	Absent
Cu	3	No	Yes	Absent
Sn	3	No	No	N/A
Cr	3	No	Yes	Absent

**Absent: less than 30% ICH Q3D Option 1 limit.*